Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRDM-14
- Development stage
- Preclinical
- Lead developer
- ARIZ Precision Medicine
- Modality
- Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
PRDM-14 is a preclinical therapeutic candidate developed by ARIZ Precision Medicine for the treatment of breast cancer. The drug targets the PR domain zinc finger protein 14 (PRDM14), an epigenetic regulator and transcription factor that is frequently overexpressed in breast cancer and is associated with the maintenance of cancer stemness, tumor progression, and resistance to therapy. PRDM-14 is formulated using ARIZ's proprietary Targeted Drug Delivery System (T-DDS), a nanotechnology platform designed to deliver therapeutic payloads (such as siRNA or antisense oligonucleotides) specifically to tumor cells while minimizing off-target effects. The program is currently in the proof-of-principle stage, with plans to transition into animal model studies to demonstrate proof-of-concept.
- Other names
- PRDM14 inhibitorPRDM-14 inhibitorPRDM 14 inhibitor
02
Targets
PRDM14 (PR domain zinc finger protein 14 mRNA)
Beyond the preview
Go deeper on PRDM-14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRDM-14.